Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
ANGLE plc ( (GB:AGL) ) has issued an announcement.
ANGLE plc has announced the posting of its audited Annual Report and Financial Statements for the year ending December 31, 2024, along with the Notice of its Annual General Meeting (AGM) scheduled for June 30, 2025. The AGM will be held at the Surrey Technology Centre, where shareholders can expect a business update following the formal proceedings. This announcement underscores ANGLE’s commitment to transparency and shareholder engagement, potentially impacting its market perception and stakeholder confidence.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
More about ANGLE plc
ANGLE plc is a world-leading liquid biopsy company specializing in innovative circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. Its primary product, the Parsortix® PC1 System, is FDA cleared and enables comprehensive downstream analysis of CTCs from blood samples. The company focuses on clinical services and diagnostic products, operating GCLP-compliant laboratories for custom assay development and clinical trial testing.
Average Trading Volume: 1,315,441
Technical Sentiment Signal: Sell
Current Market Cap: £22.58M
For a thorough assessment of AGL stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue